Molecular therapy in pancreatic adenocarcinoma.
Pancreatic cancer is one of the commonest causes of death from cancer. Despite therapy with surgery, conventional chemotherapy, and radiation, 5-year survival for patients with this diagnosis remains poor. However, advances in the molecular understanding of this malignant disease over the past 5 years might lead to new treatment strategies. Strategies of gene therapy, antiangiogenic treatments, immunotherapy, and signal-transduction inhibition are in preclinical development. This review presents an overview of molecular therapy in pancreatic cancer.
MacKenzie
Mary J
MJ
Juravinski Cancer Centre, Hamilton, Ontario Canada. mary.mackenzie@hrcc.on.ca
D000230:Adenocarcinoma / Q000628:therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy; D010190:Pancreatic Neoplasms / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal